信隆健康(002105) - 2024 Q2 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 7 million and 10 million yuan, representing a decrease of 77.55% compared to the same period last year, where it was 31.18 million yuan[3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 4 million and 7 million yuan, a decrease of 82.13% from 22.38 million yuan in the previous year[3]. - The basic earnings per share is expected to be between 0.019 yuan and 0.027 yuan, down from 0.086 yuan per share in the same period last year[3]. Performance Decline Factors - The decline in performance is attributed to high inventory levels among end customers, ongoing geopolitical conflicts, and a lack of significant demand growth in overseas markets[5]. - The prices of major raw materials have increased by nearly 10% compared to the previous year, negatively impacting the company's performance[5]. Forecast and Advisory - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by registered accountants[4]. - Investors are advised to make cautious decisions and be aware of investment risks[7].